Bile Acid Sequestrants for LDL-Cholesterol Lowering
Bile acid sequestrants should be considered when LDL-C remains ≥100 mg/dL despite maximally tolerated statin plus ezetimibe therapy in patients with baseline LDL-C ≥190 mg/dL and fasting triglycerides ≤300 mg/dL. 1
Specific Clinical Threshold
The 2019 AHA/ACC guideline provides the most explicit recommendation for bile acid sequestrant use 1:
- Baseline LDL-C: ≥190 mg/dL
- On-treatment requirement: <50% LDL-C reduction achieved
- Current therapy: Maximally tolerated statin + ezetimibe
- Triglyceride requirement: Fasting TG ≤300 mg/dL (<3.4 mmol/L)
- Recommendation strength: Class IIb (may be considered)
Treatment Algorithm
The hierarchical approach for severe hypercholesterolemia follows this sequence 1:
- First-line: Maximally tolerated statin therapy
- Second-line: Add ezetimibe 10 mg if LDL-C ≥100 mg/dL or <50% reduction achieved
- Third-line: Add bile acid sequestrant if still inadequate response with above criteria met
Important Caveats
Triglyceride threshold is critical: Bile acid sequestrants are contraindicated when triglycerides exceed 300 mg/dL, as they can paradoxically worsen hypertriglyceridemia 1, 2. This is a common pitfall to avoid.
Not for routine ASCVD patients: The 2022 ACC Expert Consensus 3 mentions bile acid sequestrants only as an alternative when patients cannot tolerate statins or ezetimibe in the context of persistent LDL-C ≥70 mg/dL. They are not part of the primary treatment algorithm for typical ASCVD patients.
Alternative Considerations
When the above criteria are met but LDL-C remains elevated, PCSK9 inhibitors may be preferred over bile acid sequestrants, particularly in 1:
- Heterozygous FH with LDL-C ≥100 mg/dL on statin + ezetimibe
- Baseline LDL-C ≥220 mg/dL with on-treatment LDL-C ≥130 mg/dL
Expected Efficacy
When added to statin therapy, bile acid sequestrants provide an additional 16.2 percentage point reduction in LDL-C on average 4, with monotherapy effects ranging from 15-26% LDL-C reduction 5.